Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Chordia Therapeutics Inc. ( (JP:190A) ) has provided an update.
Chordia Therapeutics announced that rogocekib, its CLK inhibitor for the treatment of Refractory or Relapsed Acute Myologic Lymphoma (AML), has been granted Orphan Drug Designation by the FDA in the United States. This designation provides various developmental and financial benefits, including application fee exemptions, tax reductions, and exclusive market rights for seven years post-approval, paving the way for the potential commercialization of rogocekib.
More about Chordia Therapeutics Inc.
Chordia Therapeutics Inc. is a clinical-stage biotech company based in Fujisawa, Kanagawa Prefecture, Japan, focused on the research and development of novel cancer therapies. Its lead asset, rogocekib, is a CLK inhibitor currently undergoing Phase 1/2 clinical trials in the U.S. The company is also working on other preclinical assets, such as CTX-439, a CDK12 inhibitor, and GCN2 inhibitors.
YTD Price Performance: -1.58%
Average Trading Volume: 7,098,076
Technical Sentiment Consensus Rating: Hold
See more insights into 190A stock on TipRanks’ Stock Analysis page.